ACM
ONCT

Anfield Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Anfield Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-92
Closed -$9K – 271
2021
Q2 		$9K Buy
+92
New +$10.9K ﹤0.01% 170
2020
Q1 		– Sell
-92
Closed -$8K – 410
2019
Q4 		$8K Buy
+92
New +$9.52K ﹤0.01% 344

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Anfield Capital Management's ONCT Position: Q3 2021 in Review

Anfield Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2021, closing a stake of 92 shares — an estimated $9K sold.

Anfield Capital Management first reported a position in ONCT in Q4 2019 and held it in 2 quarters. The position peaked at $9K in Q2 2021. 76 funds tracked by Wall St. Rank hold ONCT as of Q3 2021.

  • Anfield Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Anfield Capital Management sold 92 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $9K.
  • Anfield Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Anfield Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $9K in Q2 2021.
  • 76 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Anfield Capital Management's 13F filing for Q3 2021, filed 4 Nov 2021.